Nextcure Stock Investor Sentiment

NXTC Stock  USD 0.78  0.03  3.99%   
About 71 percent of all NextCure's shareholders are curious in acquiring. The analysis of the overall investor sentiment regarding NextCure suggests that quite a large number of traders are confidant. The current market sentiment, together with NextCure's historical and current headlines, can help investors time the market. In addition, many technical investors use NextCure stock news signals to limit their universe of possible portfolio assets.
  

NextCure Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards NextCure can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
48.7%
53.8%
50.9%
51.0%
48.8%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at gurufocus.com         
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
Gurufocus Stories at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3
Macroaxis News
over three months ago at gurufocus.com         
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with ...
Gurufocus Stories at Macroaxis
over three months ago at globenewswire.com         
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Bett...
Macroaxis News: globenewswire.com
over three months ago at gurufocus.com         
Logos Global Management LP Reduces Stake in NextCure Inc
Gurufocus Stories at Macroaxis
over three months ago at news.google.com         
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc - GuruFocus.com
Google News at Macroaxis
over three months ago at simplywall.st         
Heres Why Were Watching NextCures Cash Burn Situation
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
NextCure to Discuss Innovative Cancer Therapies - TipRanks
Google News at Macroaxis
over three months ago at finance.yahoo.com         
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
Yahoo News
over three months ago at globenewswire.com         
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo ...
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
Intuitive Surg Inc Quote - Press Release - The Globe and Mail
Google News at Macroaxis
over three months ago at globenewswire.com         
NextCure to Give Two Presentations at Society for Immunotherapy of CancerAnnual Meeting
Macroaxis News: globenewswire.com
over three months ago at www.macroaxis.com         
Acquisition by Jones Elaine V of 14250 shares of NextCure at 1.62 subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO ...
Yahoo News
Far too much social signal, news, headlines, and media speculation about NextCure that are available to investors today. That information is available publicly through NextCure media outlets and privately through word of mouth or via NextCure internal channels. However, regardless of the origin, that massive amount of NextCure data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NextCure news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NextCure relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NextCure's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NextCure alpha.

NextCure Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.1512345678Dec2025Feb -40-30-20-100
JavaScript chart by amCharts 3.21.15NextCure NextCure Dividend Benchmark Dow Jones Industrial
       Timeline  
1
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
11/26/2024
2
NextCure stock hits 52-week low at 0.99 amid market challenges - Investing.com
12/16/2024
3
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers
01/10/2025
4
Acquisition by Houston John G of 28500 shares of NextCure at 9.14 subject to Rule 16b-3
01/27/2025
5
NextCure, Inc. Short Interest Update
01/30/2025
6
Insider Trading
01/31/2025
7
NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance
02/05/2025
8
Peapod Lane Capital LLC Invests 311,000 in NextCure, Inc.
02/13/2025

Complementary Tools for NextCure Stock analysis

When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance